ZA200702790B - Thrombin receptor antagonists - Google Patents
Thrombin receptor antagonistsInfo
- Publication number
- ZA200702790B ZA200702790B ZA200702790A ZA200702790A ZA200702790B ZA 200702790 B ZA200702790 B ZA 200702790B ZA 200702790 A ZA200702790 A ZA 200702790A ZA 200702790 A ZA200702790 A ZA 200702790A ZA 200702790 B ZA200702790 B ZA 200702790B
- Authority
- ZA
- South Africa
- Prior art keywords
- receptor antagonists
- thrombin receptor
- thrombin
- antagonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61751404P | 2004-10-08 | 2004-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200702790B true ZA200702790B (en) | 2008-09-25 |
Family
ID=36061549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200702790A ZA200702790B (en) | 2004-10-08 | 2007-04-03 | Thrombin receptor antagonists |
Country Status (17)
Country | Link |
---|---|
US (1) | US7488752B2 (xx) |
EP (2) | EP1802609A2 (xx) |
JP (1) | JP2008515899A (xx) |
KR (1) | KR20070101216A (xx) |
CN (1) | CN101072772A (xx) |
AR (1) | AR054611A1 (xx) |
AU (1) | AU2005294490A1 (xx) |
BR (1) | BRPI0518159A (xx) |
CA (1) | CA2582639A1 (xx) |
EC (1) | ECSP077372A (xx) |
IL (1) | IL182355A0 (xx) |
MX (1) | MX2007004197A (xx) |
NO (1) | NO20072344L (xx) |
RU (1) | RU2408594C2 (xx) |
TW (1) | TW200626584A (xx) |
WO (1) | WO2006041872A2 (xx) |
ZA (1) | ZA200702790B (xx) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
AR060354A1 (es) * | 2006-04-06 | 2008-06-11 | Schering Corp | Terapias de combinacion antagonistas receptor trombina (tra) |
US8828966B2 (en) * | 2006-10-03 | 2014-09-09 | Claire Mitchell | Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors |
US8153664B2 (en) * | 2006-10-04 | 2012-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
US8227412B2 (en) * | 2007-03-29 | 2012-07-24 | Tsopanoglou Nikos E | Bioactive parstatin peptides and methods of use |
WO2008128038A2 (en) * | 2007-04-13 | 2008-10-23 | The Scripps Research Institute | Methods and compositions for treating cardiac dysfunctions |
WO2011128421A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi | Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren |
EP2558462B1 (de) | 2010-04-16 | 2014-10-22 | Sanofi | Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren |
US9340530B2 (en) * | 2012-03-06 | 2016-05-17 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
MX2014013428A (es) * | 2012-05-04 | 2015-02-04 | Novartis Ag | Moduladores de la ruta del complemento y usos de los mismos. |
CN105229003B (zh) | 2013-03-14 | 2017-03-15 | 诺华股份有限公司 | 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物 |
EP3035928B1 (en) | 2013-08-22 | 2023-10-18 | Merck Sharp & Dohme LLC | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
WO2015026693A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
WO2015026685A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
CN104447927A (zh) * | 2013-09-13 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 坎格雷洛一水合物晶体及其制备方法 |
CN104447928A (zh) * | 2013-09-13 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 坎格雷洛二水化合物 |
US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
WO2016058144A1 (en) * | 2014-10-15 | 2016-04-21 | Merck Sharp & Dohme Corp. | Preparation and use of cyclic sulfonamide derivatives as par-1 receptor antagonists |
CN105732595B (zh) * | 2015-12-22 | 2018-08-28 | 山东大学 | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 |
TW201738237A (zh) * | 2016-04-22 | 2017-11-01 | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
CN1290265A (zh) * | 1997-11-25 | 2001-04-04 | 先灵公司 | 凝血酶受体拮抗剂 |
US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
ES2291323T3 (es) * | 2000-06-15 | 2008-03-01 | Schering Corporation | Antagonistas de receptores de trombina. |
KR100960170B1 (ko) * | 2001-10-18 | 2010-05-26 | 쉐링 코포레이션 | 트롬빈 수용체 길항제로서의 힘바신 동족체 |
US7086034B2 (en) * | 2002-06-28 | 2006-08-01 | Canon Kabushiki Kaisha | Method, program, and storage medium for acquiring logs |
-
2005
- 2005-10-05 EP EP05802841A patent/EP1802609A2/en not_active Withdrawn
- 2005-10-05 AU AU2005294490A patent/AU2005294490A1/en not_active Abandoned
- 2005-10-05 BR BRPI0518159-3A patent/BRPI0518159A/pt not_active IP Right Cessation
- 2005-10-05 KR KR1020077007897A patent/KR20070101216A/ko not_active Application Discontinuation
- 2005-10-05 JP JP2007535765A patent/JP2008515899A/ja active Pending
- 2005-10-05 CN CNA2005800422977A patent/CN101072772A/zh active Pending
- 2005-10-05 EP EP09156735.4A patent/EP2075250B1/en active Active
- 2005-10-05 RU RU2007116850/04A patent/RU2408594C2/ru not_active IP Right Cessation
- 2005-10-05 MX MX2007004197A patent/MX2007004197A/es active IP Right Grant
- 2005-10-05 CA CA002582639A patent/CA2582639A1/en not_active Abandoned
- 2005-10-05 US US11/243,708 patent/US7488752B2/en active Active
- 2005-10-05 WO PCT/US2005/035745 patent/WO2006041872A2/en active Application Filing
- 2005-10-06 AR ARP050104221A patent/AR054611A1/es not_active Application Discontinuation
- 2005-10-06 TW TW094135027A patent/TW200626584A/zh unknown
-
2007
- 2007-04-01 IL IL182355A patent/IL182355A0/en unknown
- 2007-04-03 ZA ZA200702790A patent/ZA200702790B/xx unknown
- 2007-04-04 EC EC2007007372A patent/ECSP077372A/es unknown
- 2007-05-07 NO NO20072344A patent/NO20072344L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2007004197A (es) | 2007-06-15 |
RU2007116850A (ru) | 2008-11-20 |
RU2408594C2 (ru) | 2011-01-10 |
EP2075250A3 (en) | 2009-10-14 |
EP1802609A2 (en) | 2007-07-04 |
CN101072772A (zh) | 2007-11-14 |
EP2075250B1 (en) | 2015-03-04 |
CA2582639A1 (en) | 2006-04-20 |
AU2005294490A1 (en) | 2006-04-20 |
US7488752B2 (en) | 2009-02-10 |
EP2075250A2 (en) | 2009-07-01 |
AR054611A1 (es) | 2007-07-04 |
BRPI0518159A (pt) | 2008-11-04 |
NO20072344L (no) | 2007-07-04 |
WO2006041872A3 (en) | 2007-01-04 |
KR20070101216A (ko) | 2007-10-16 |
IL182355A0 (en) | 2007-07-24 |
TW200626584A (en) | 2006-08-01 |
WO2006041872A2 (en) | 2006-04-20 |
ECSP077372A (es) | 2007-05-30 |
JP2008515899A (ja) | 2008-05-15 |
US20060079684A1 (en) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200702790B (en) | Thrombin receptor antagonists | |
IL174538A0 (en) | Thrombin receptor antagonists | |
TWI346553B (en) | Chemokine receptor antagonists | |
TWI341198B (en) | Hydroisoindoline tachykinin receptor antagonists | |
ZA200708067B (en) | Spirocyclic thrombin receptor antagonists | |
TWI318206B (en) | Histamine-3 receptor antagonists | |
EP1765805A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
EP1871752A4 (en) | ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR | |
EP1799672A4 (en) | CGRP RECEPTOR ANTAGONIST | |
TWI348467B (en) | Nk1 antagonists | |
EP1874302A4 (en) | ANTAGONISTS OF ANGIOTENSIN II RECEPTORS | |
IL237513A0 (en) | Piperazindiones as oxytocin receptor antagonists | |
ZA200806065B (en) | Oxazoloisoquinoline derivatives as thrombin receptor antagonists | |
EP1812008A4 (en) | ANTAGONISTS OF THE IL-8 RECEPTOR | |
EP1898905A4 (en) | ANTAGONISTS OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS | |
ZA200605574B (en) | Hydroisoindoline tachykinin receptor antagonists | |
GB0525029D0 (en) | Receptor Antagonist | |
GB0414798D0 (en) | Receptor | |
SI1711465T1 (sl) | Antagonisti hidroizoindolin tahikininskega receptorja | |
GB0413872D0 (en) | Receptor | |
GB0404309D0 (en) | Receptor | |
GB0404584D0 (en) | Receptor | |
GB0417119D0 (en) | Receptor | |
GB0423327D0 (en) | Receptor | |
GB0427025D0 (en) | Receptor |